Public Health Service Act

MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook

Retrieved on: 
Friday, December 29, 2023

MARIETTA, Ga., Dec. 29, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update regarding AXIOFILL and reiterated its outlook for 2023 full year net sales growth and fourth quarter adjusted EBITDA margin.

Key Points: 
  • Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety
    MARIETTA, Ga., Dec. 29, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update regarding AXIOFILL and reiterated its outlook for 2023 full year net sales growth and fourth quarter adjusted EBITDA margin.
  • However, on December 21, 2023, MIMEDX received a Warning Letter from FDA reiterating the agency’s position on AXIOFILL.
  • MIMEDX plans to provide commentary about this matter during its upcoming fourth quarter and year end 2023 conference call in late-February.
  • As such, we are also reiterating our expectations for full year 2023 net sales in the high-teens and fourth quarter adjusted EBITDA margin above 20%.

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Retrieved on: 
Monday, November 6, 2023

NEW HAVEN, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).

Key Points: 
  • NIDA has requested Columbia University, the trial coordinator, to add a fourth site to target trial completion in 2024.
  • After this time, BioXcel Therapeutics plans to seek FDA feedback on potential registrational paths.
  • “With BXCL501, we are excited about the potential to treat patients who are physically dependent on illicit and prescription opioids.
  • In addition to OUD as an indication, BioXcel Therapeutics has been awarded key opportunities for the development of BXCL501 in post-traumatic stress disorder and alcohol use disorder.

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

Retrieved on: 
Monday, October 23, 2023

Based on the results of the LIBERTY UC and LIBERTY CD studies, ZYMFENTRA demonstrated superiority in the primary endpoints of clinical remission (UC and CD) and endoscopic response (CD) compared to placebo as maintenance therapy after induction therapy of intravenous formulation of infliximab in patients with UC and CD, over a 54-week study period.

Key Points: 
  • Based on the results of the LIBERTY UC and LIBERTY CD studies, ZYMFENTRA demonstrated superiority in the primary endpoints of clinical remission (UC and CD) and endoscopic response (CD) compared to placebo as maintenance therapy after induction therapy of intravenous formulation of infliximab in patients with UC and CD, over a 54-week study period.
  • The overall safety profile of ZYMFENTRA was similar to that of placebo during maintenance period in both studies with no new safety signals seen.2,3
    “There remains an unmet need for patients who suffer from the day-to-day burden of living with moderately to severely active Crohn’s disease and ulcerative colitis,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA.
  • “As someone dedicated to improving the lives of patients with IBD, I am excited to see data supporting the efficacy and safety of a new formulation offering convenience and improved access to a well-known and proven drug,” said Dr. Andres Yarur of Cedars-Sinai Medical Center.
  • ZYMFENTRA will be under patent protection by 2037 for its dosage form and route of administration by 2040.

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Retrieved on: 
Tuesday, September 19, 2023

LEXINGTON, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel.

Key Points: 
  • LEXINGTON, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel.
  • The FDA 510(k) clearance allows the company to immediately begin marketing and selling the T2Biothreat Panel in the U.S. market.
  • The U.S. clinical evaluation to support the FDA 510(k) submission included testing of the T2Biothreat Panel at MRIGlobal, a Biosafety Level 3 laboratory specializing in biothreat pathogens, and Ochsner Medical Center.
  • The T2Biothreat Panel is able to detect the six aforementioned biothreat pathogens within four hours providing clinicians with the needed information to appropriately treat infected patients.

What does ending the emergency status of the COVID-19 pandemic in the US mean in practice? 4 questions answered

Retrieved on: 
Wednesday, May 10, 2023

The COVID-19 pandemic’s public health emergency status in the U.S. expires on May 11, 2023.

Key Points: 
  • The COVID-19 pandemic’s public health emergency status in the U.S. expires on May 11, 2023.
  • And on May 5, the World Health Organization declared an end to the COVID-19 public health emergency of international concern, or PHEIC, designation that had been in place since Jan. 30, 2020.
  • While the global emergency status has ended, COVID-19 is still an “established and ongoing health issue,” he said.

1. What does ending the national emergency phase of the pandemic mean?

    • Ending the federal emergency reflects both a scientific and political judgment that the acute phase of the COVID-19 pandemic crisis has ended and that special federal resources are no longer needed to prevent disease transmission across borders.
    • In practical terms, it means that two declarations – the federal Public Health Emergency, first declared on Jan. 31, 2020, and the COVID-19 national emergency that former President Donald Trump announced on March 13, 2020, are expiring.
    • Declaring those emergencies enabled the federal government to cut through mountains of red tape to respond to the pandemic more efficiently.

2. What domestic policies are changing?

    • Another analysis projected that as many as 24 million people will be kicked off the Medicaid rolls.
    • Before the pandemic, states required people to prove every year that they met income and other eligibility requirements.
    • In March 2020, Congress enacted a continuous enrollment provision in Medicaid that prevented states from removing anyone from their rolls during the pandemic.
    • In a December 2022 appropriations bill, Congress passed a provision that ended continuous enrollment on March 31, 2023.
    • The array of telehealth services that Medicare began covering during the pandemic will continue to be covered through December 2024.

3. What does this mean for the status of the pandemic?

    • But declaring an end to the emergency doesn’t mean a return to business as usual.
    • She called for more federally funded research into therapeutics and durable vaccines that protect against many variants.
    • With the end of the emergency, the CDC is also changing the way it presents its COVID-19 data to a “sustainable national COVID-19 surveillance” model.

4. How will state and local pandemic measures be affected?

    • Most U.S. states, however, have ended their own public health emergency declarations.
    • Marian Moser Jones receives funding from the National Endowment for the Humanities and The American Public Health Association.
    • In the past she has received funding from the National Institutes of Health and the American Association for the History of Nursing, as well as the State of Maryland.

National pharmacy offers relief to millions losing health insurance on May 11

Retrieved on: 
Tuesday, May 2, 2023

Rx Outreach, the nation's largest online nonprofit pharmacy, offers help to millions losing health insurance on May 11.

Key Points: 
  • Rx Outreach, the nation's largest online nonprofit pharmacy, offers help to millions losing health insurance on May 11.
  • A PHE for Covid-19 was declared by the Secretary of the Department of Health and Human Services January 2020, pursuant to Section 319 of the Public Health Service Act .
  • "We are part of America's healthcare safety net, a trusted, affordable pharmacy at the ready to help people live their healthiest lives despite losing health insurance or other challenges."
  • Patients can be uninsured, underinsured, on Medicare, Medicaid, or other health insurance and still qualify for prescription support.

Healthcare Ready report to Congress reveals communities are left vulnerable to future pandemics, disasters due to inconsistent regional capabilities

Retrieved on: 
Tuesday, January 31, 2023

WASHINGTON, Jan. 31, 2023 /PRNewswire-PRWeb/ -- Healthcare Ready has released a report to Congress calling for greater federal oversight, and increased communication, coordination and preparedness among those responsible for organizing and responding to public health emergencies. The nonprofit organization works to strengthen the U.S. health care system and assist all communities in planning for, responding to, and recovering from disasters and disease pandemics.

Key Points: 
  • WASHINGTON, Jan. 31, 2023 /PRNewswire-PRWeb/ -- Healthcare Ready has released a report to Congress calling for greater federal oversight, and increased communication, coordination and preparedness among those responsible for organizing and responding to public health emergencies.
  • The nonprofit organization works to strengthen the U.S. health care system and assist all communities in planning for, responding to, and recovering from disasters and disease pandemics.
  • Launched in 2019, the evaluation includes lessons learned from the COVID-19 pandemic as well as prior public health emergencies.
  • Increase funding for federal preparedness and response to strengthen national and regional capabilities, help to achieve better outcomes after disasters, and contribute to ensuring our nation's health security against future public health threats.

Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration

Retrieved on: 
Thursday, December 22, 2022

Celltrion USA today announced the submission of a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act (a “stand-alone” BLA) for lead product candidate, CT-P13 SC, which is the subcutaneous formulation of infliximab to the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Celltrion USA today announced the submission of a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act (a “stand-alone” BLA) for lead product candidate, CT-P13 SC, which is the subcutaneous formulation of infliximab to the U.S. Food and Drug Administration (FDA).
  • The planned initial submission package will seek approval of CT-P13 SC for the treatment of inflammatory bowel disease (IBD).
  • “This BLA submission marks a significant milestone for Celltrion and we are working with the FDA to bring this innovative treatment to the U.S. market,” said Hyoung Ki Kim, Vice Chairman & CEO, Celltrion Healthcare.
  • “In addition, CT-P13 SC releases the burden of having to travel to treatment for IV infusions, reducing treatment-related travel costs for patients and caregivers.”

Vista Consulting Team, Business Resource for Plaintiff Law Firms, Peers Into Future of Plaintiff Law Firms in the US

Retrieved on: 
Thursday, August 18, 2022

His consulting firm, Vista Consulting Team, has been "behind the green curtain" of more than 200 plaintiff firms across the United States and Canada.

Key Points: 
  • His consulting firm, Vista Consulting Team, has been "behind the green curtain" of more than 200 plaintiff firms across the United States and Canada.
  • "These firms are listening to the business people that are creeping into the law firm space, just as the banks and accountants did.
  • The impending change, McKey said, means that law firms should concentrate on running a law practice as a business.
  • Tim McKey is the owner and co-founder of Vista, a consulting group aimed at helping plaintiff law firms improve operations, culture, and leadership.

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update

Retrieved on: 
Friday, May 13, 2022

This past quarter was marked by the achievement of the most important milestone to date for Outlook Therapeutics the submission of our BLA for ONS-5010.

Key Points: 
  • This past quarter was marked by the achievement of the most important milestone to date for Outlook Therapeutics the submission of our BLA for ONS-5010.
  • Outlook Therapeutics wet AMD clinical program for ONS-5010 consists of three completed clinical trials, NORSE ONE, NORSE TWO, and NORSE THREE.
  • With the successful completion of these clinical trials, Outlook Therapeutics submitted its BLA under the Public Health Service Act (PHSA) 351(a) regulatory pathway in March 2022.
  • We believe Outlook Therapeutics is in a strong financial position, stated Lawrence A. Kenyon, Chief Financial Officer of Outlook Therapeutics.